ArticleThe Journal of experimental medicine2003
Leukocyte, rather than tumor-produced SPARC, determines stroma and collagen type IV deposition in mammary carcinoma.
Article in The Journal of experimental medicine, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 133 citations in OpenAlex.
- Guided immunotherapy for residual solid tumor: integrating platelets and CAR T cells to reduce post-surgical recurrence.Biomarker research · 2026Review
- Regulatory Mechanisms of SPARC Overexpression in Melanoma Progression.International journal of molecular sciences · 2025Article
- Alternative Splicing: A Critical Regulator in Human Bone Biology and Tumor Progression.Research (Washington, D.C.) · 2025Review
- Identifying luminal and basal mammary cell specific genes and their expression patterns during pregnancy.PloS one · 2022Article
- Microenvironmental modulation of the developing tumour: an immune-stromal dialogue.Molecular oncology · 2021Review
- Fibronectin mediates activation of stromal fibroblasts by SPARC in endometrial cancer cells.BMC cancer · 2021Article
- Intra-tumour heterogeneity of diffuse large B-cell lymphoma involves the induction of diversified stroma-tumour interfaces.EBioMedicine · 2020Article
- The Influence of the Extracellular Matrix in Inflammation: Findings from the SPARC-Null Mouse.Anatomical record (Hoboken, N.J. : 2007) · 2020Review
- Macrophage-derived SPARC Attenuates M2-mediated Pro-tumour Phenotypes.Journal of Cancer · 2020Article
- Quantitative proteomic analysis of cerebrospinal fluid from patients with diffuse large B-cell lymphoma with central nervous system involvement: A novel approach to diagnosis.Biomedical reports · 2019Article
- SPARC Is a New Myeloid-Derived Suppressor Cell Marker Licensing Suppressive Activities.Frontiers in immunology · 2019Article
- Metastasis in context: modeling the tumor microenvironment with cancer-on-a-chip approaches.Disease models & mechanisms · 2018Review
- Common extracellular matrix regulation of myeloid cell activity in the bone marrow and tumor microenvironments.Cancer immunology, immunotherapy : CII · 2017Review
- The role of the extracellular matrix in primary myelofibrosis.Blood cancer journal · 2017Review
- Healthy and tumoral tissue resistivity in wild-type and sparc-/- animal models.Medical & biological engineering & computing · 2016Article
- Review
- E2f3 in tumor macrophages promotes lung metastasis.Oncogene · 2016Article
- The role of secreted protein acidic and rich in cysteine (SPARC) in cardiac repair and fibrosis: Does expression of SPARC by macrophages influence outcomes?Journal of molecular and cellular cardiology · 2016Review
- Stromal fibroblast activation and their potential association with uterine fibroids (Review).Oncology letters · 2014Article
- TE-array--a high throughput tool to study transposon transcription.BMC genomics · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Secreted protein, acidic and rich in cysteine (SPARC), also known as osteonectin or BM-40, is a Ca2+-binding matricellular glycoprotein involved in development, wound healing, and neoplasia. However, the role of SPARC in tumors is ill defined mostly because it is expressed by both tumor and stromal cells, especially inflammatory cells. We analyzed the respective roles of host- and tumor-derived SPARC in wild-type and congenic SPARC knockout (SPARC-/-) mice on a BALB/c genetic background injected into the mammary fat pad with SPARC-producing mammary carcinoma cells derived from c-erB2 transgenic BALB/c mice. Reduced tumor growth but massive parenchyma infiltration, with large areas of necrosis and impaired vascularization were observed in SPARC-/- mice. Immunohistochemical analysis showed a defect in collagen type IV deposition in the stroma of lobular tumors from SPARC-/- mice. Chimeric mice expressing SPARC only in bone marrow-derived cells were able to organize peritumoral and perilobular stroma, whereas reciprocal chimeras transplanted with bone marrow from SPARC-/- mice developed tumors with less defined lobular structures, lacking assembled collagen type IV and with a parenchyma heavily infiltrated by leukocytes. Together, the data indicate that SPARC produced by host leukocytes, rather than the tumor, determines the assembly and function of tumor-associated stroma through the organization of collagen type IV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.